Meplazumab Biosimilar – Anti-CD147 mAb – Research Grade from ProteoGenix; catalogue PX-TA1619; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Meplazumab Biosimilar, also known as Anti-CD147 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Meplazumab antibody. It targets the CD147 protein, which is overexpressed in various cancers and inflammatory diseases. Meplazumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential therapeutic option for these diseases.
Meplazumab Biosimilar is a recombinant humanized monoclonal antibody that has been engineered to mimic the structure of the original Meplazumab antibody. It is composed of two heavy chains and two light chains, each consisting of variable and constant regions. The variable regions of the antibody are responsible for binding to the CD147 protein, while the constant regions determine the effector functions of the antibody.
The primary activity of Meplazumab Biosimilar is to bind to the CD147 protein and inhibit its function. CD147 is a cell surface glycoprotein that plays a crucial role in cell adhesion, migration, and invasion. It is also involved in the regulation of immune responses and is overexpressed in various cancers and inflammatory diseases. By binding to CD147, Meplazumab Biosimilar blocks its interaction with other proteins and disrupts its function, leading to a decrease in cell proliferation and migration.
In addition to its inhibitory activity, Meplazumab Biosimilar also has effector functions that can contribute to its therapeutic efficacy. These include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ADCC involves the activation of immune cells, such as natural killer cells, to target and kill cancer cells that are bound by Meplazumab Biosimilar. CDC, on the other hand, involves the activation of the complement system, which leads to the destruction of target cells.
Meplazumab Biosimilar has shown promising results in preclinical studies as a potential therapeutic option for various cancers and inflammatory diseases. It has been evaluated in several in vitro and in vivo studies, which have demonstrated its ability to inhibit cell proliferation, migration, and invasion in cancer cells. In addition, Meplazumab Biosimilar has also shown anti-inflammatory effects in models of inflammatory diseases, such as rheumatoid arthritis and multiple sclerosis.
Currently, Meplazumab Biosimilar is being evaluated in clinical trials for the treatment of multiple myeloma, non-small cell lung cancer, and inflammatory bowel disease. These trials aim to assess the safety and efficacy of Meplazumab Biosimilar in patients and determine its potential as a therapeutic option for these diseases.
In summary, Meplazumab Biosimilar is a recombinant humanized monoclonal antibody that targets the CD147 protein, which is overexpressed in various cancers and inflammatory diseases. Its primary activity is to inhibit the function of CD147, and it also has effector functions that can contribute to its therapeutic efficacy. Meplazumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential therapeutic option for multiple myeloma, non-small cell lung cancer, and inflammatory bowel disease. Further research and clinical trials will determine the full potential of Meplazumab Biosimilar as a therapeutic antibody.
ProteoGenix catalogue number PX-TA1619. For research use only.
Target: Meplazumab Biosimilar – Anti-CD147 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Meplazumab Biosimilar – Anti-CD147 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
